Jincheng Pharm: Subsidiary products are expected to be selected for the 11th batch of national centralized drug procurement

On October 28th, Jincheng Pharm announced that its wholly-owned subsidiary Beijing Jincheng Tail Pharmaceutical Co., Ltd. and its holding subsidiary Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd. participated in the bidding for the 11th batch of national centralized drug procurement organized by the National Organization for Drug Centralized Procurement and Use Joint Procurement Office. Jincheng Tail's Rebapamide tablets and Jincheng Jinsu's injectable Cefazolin Sodium are expected to be selected in this centralized procurement

Jincheng Pharm: Morphine Nitrazepam Sodium Injection has obtained a drug registration certificate

Jincheng Pharm's subsidiary, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd., has obtained a drug registration certificate issued by the National Medical Products Administration. The registered product is Morpholine Nitrazole Sodium Injection. This medication is a 5-nitroimidazole antibacterial drug, suitable for various adult infections caused by sensitive bacteria, including gynecological pelvic inflammatory disease and suppurative appendicitis

Jincheng Pharm: Subsidiary receives approval notice for drug supplementary application

Jincheng Pharm's subsidiary Beijing Jincheng Tail Pharmaceutical Co., Ltd. has received the approval notice for the supplementary application of drugs from the National Medical Products Administration, involving changes in the types and quantities of excipients, processes, and quality standards for Progesterone cream. According to IMS data, the global sales of Progesterone formulations are projected to be USD 78.0961 million, USD 94.3352 million, and USD 104 million from 2022 to 2024, respectively. This approval will enhance product competitiveness, but will have a limited impact on current performance

A-share innovative drug concept stocks fluctuated lower, with BETTA PHARMACEUTICALS falling over 10%, Jincheng Pharm, Konruns, Baillie Tianheng, Olymvax Biopharmaceuticals, and CCHT all dropping more than 5%

The actual controller of Jincheng Pharm received a notice of administrative penalty in advance

Jincheng Pharm announced that its actual controller Zhao Yeqing received the "Notice of Administrative Penalty" from the China Securities Regulatory Commission, due to suspected manipulation of the securities market. Zhao Yeqing, Wang Zhen, and Liu Feng will each be fined 3 million yuan, with Zhao Yeqing bearing 1.5 million yuan and facing a 4-year market ban, while Wang Zhen faces a 3-year ban. Zhao Yeqing will apply for a hearing in accordance with the law